• Pangaea Ventures Team

    Pangaea Ventures Celebrates Final Close of Fifth Fund at $85M

  • Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada and British Columbia

  • What is hard tech (and why we are so passionate about it?)

  • Why We Invested in Green Theme Technologies

Portfolio Updates Mitchell Ballentine Portfolio Updates Mitchell Ballentine

Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and Development

Kanvas Biosciences, a Pangaea Ventures portfolio company, has published new research on its High-Phylogenetic-Resolution Spatial Mapping (HiPR-Map) Platform spectral imaging technology. This novel tool promises to transform how researchers visualize and analyze the complexities of the microbiome.

Read More
Portfolio Updates Sarah Applebaum Portfolio Updates Sarah Applebaum

Floré Unveils World’s First Line of Probiotics for Neurodiversity

Floré, a leader in gut health testing and customized probiotics, has launched its new line of probiotics specifically designed for neurodiversity. The new products, Pathways Support and Mood Support are formulated using extensive data from the company’s groundbreaking research study conducted in partnership with Arizona State University, which explored the positive impact of customized probiotic supplementation on individuals with autism spectrum disorder (ASD).

Read More
Portfolio Updates Sarah Applebaum Portfolio Updates Sarah Applebaum

Tidal Grow® AgriScience Receives USDA Fertilizer Production Expansion Grant to Expand Leading Regenerative Fertilizer Production

Tidal Grow® AgriScience, a division of Tidal Vision Products Inc., has been awarded a Fertilizer Production Expansion Program (FPEP) grant by the USDA. This funding significantly increases production of the popular seafood hydrolysate liquid fertilizers Oceanic® and SeaPhos®.

Read More
Portfolio Updates Sarah Applebaum Portfolio Updates Sarah Applebaum

Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing

Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised $12.5 million in additional funding co-led by existing investors DCVC and Lions Capital LLC, and participation from FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures as well as existing investors.

Read More